苑东生物(688513.SH)发布上半年业绩，归母净利润1.37亿元，下降6.77%

Core Viewpoint - Yuan Dong Biotech (688513.SH) reported a decline in both revenue and net profit for the first half of 2025, primarily due to the impact of national centralized procurement and increased stock incentive expenses [1] Financial Performance - The company's operating revenue for the first half of 2025 was 654 million yuan, representing a year-on-year decrease of 2.25% [1] - The net profit attributable to shareholders was 137 million yuan, down 6.77% compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 104 million yuan, reflecting an 8.68% decrease year-on-year [1] - Basic earnings per share stood at 0.77 yuan [1] Factors Influencing Performance - The decline in revenue and net profit is mainly attributed to the implementation of the tenth batch of national centralized procurement, which led to a decrease in sales revenue from chemical preparations [1] - Additionally, the increase in stock incentive expenses during the reporting period contributed to the decline in profitability [1]